Halozyme Therapeutics, Inc. (NASDAQ:HALO) is identified as one of the most profitable biotech stocks to invest in. H.C. Wainwright analyst Mitchell Kapoor maintained a Buy rating on HALO with a price target of $90. The recent success of the MajesTEC-3 trial demonstrated significant improvements in progression-free survival (PFS) and overall survival (OS) compared to existing treatments.

The MajesTEC-3 trial combines Johnson & Johnson’s DARZALEX Faspro with TECVAYLI, enhancing Halozyme Therapeutics, Inc.’s (NASDAQ:HALO) royalty base. The trial’s outcome supports DARZALEX-based regimens, as DARZALEX Faspro utilizes the company’s ENHANZE technology. HALO is a biopharmaceutical technology platform company that develops drug-device combination products through advanced auto-injector technology.

While HALO offers investment potential, some AI stocks may provide greater upside and lower downside risk. For those seeking an undervalued AI stock benefiting from Trump-era tariffs and onshoring trends, consider exploring the best short-term AI stock. Visit Insider Monkey for more insights on potential stock opportunities.

Read more at Yahoo Finance: H.C. Wainwright Maintains a Buy on Halozyme Therapeutics (HALO), Keeps the PT at $90